The DOI matches its Crossref record.
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tofacitinib and baricitinib are efficacious against RA and have been approved for the treatment of RA.”
From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as Taylor et al., 2017
Experimental — accuracy not yet measuredIn the citing paper
“baricitinib was associated with significantly greater clinical improvement”
From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as Taylor et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 22
- 10.1016/S0140-6736(07)60784-3 · DOI
- 10.1136/annrheumdis-2012-202576 · DOI
- 10.1136/annrheumdis-2014-206478 · DOI
- 10.3899/jrheum.150613 · DOI
- 10.1056/NEJMoa1507247 · DOI
- 10.1002/art.1780380602 · DOI
- van der Heijde D, 2000, J Rheumatol, 27, 261
- van der Heijde DM, 2004, J Rheumatol Suppl, 69, 46
- 10.1002/art.1780230202 · DOI
- Fries JF, 1982, J Rheumatol, 9, 789
- 10.1093/rheumatology/keg072 · DOI
- Aletaha D, 2005, Clin Exp Rheumatol, 23, S100
- 10.1186/ar1740 · DOI
- 10.1002/art.1780380107 · DOI
- 10.1002/sim.3495 · DOI · Paper page
- 10.1002/sim.5974 · DOI
- 10.1136/ard.2008.105197 · DOI · Paper page
- 10.1002/art.37711 · DOI
- 10.1002/art.21519 · DOI
- 10.1016/j.clinthera.2011.05.044 · DOI
- 10.1002/art.34498 · DOI
- 10.1136/annrheumdis-2013-204577 · DOI
Cited by
Sorted by citations
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin, P., Xu, X., Deng, C., Liu, S., Wang, Y., Zhou, X., Ma, H., Wei, D., & Sun, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106210 · Cited by 1,010
Targeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 904
Properties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach
Tanaka, Y., Luo, Y., O’Shea, J. J., & Nakayamada, S. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00726-8 · Cited by 501
Self-citation
Metadata
- Authors
- Taylor, P. C., Keystone, E. C., van der Heijde, D., Weinblatt, M. E., del Carmen Morales, L., Reyes Gonzaga, J., Yakushin, S., Ishii, T., Emoto, K., Beattie, S., Arora, V., Gaich, C., Rooney, T., Schlichting, D., Macias, W. L., de Bono, S., & Tanaka, Y.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-02-16
- Volume
- 376
- Issue
- 7
- Pages
- 652-662
- ISSN
- 0028-4793
- 1533-4406
- Cited by
- 872
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
